Prostate Cancer - Results from #180

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. June 15, 2021

Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study. June 15, 2021

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. June 15, 2021

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. June 15, 2021

Association of Age with Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance. June 14, 2021

Perceptions of wellbeing and quality of life following participation in a community-based pre-operative exercise programme in men with newly diagnosed prostate cancer: A qualitative pilot study. June 14, 2021

Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. June 14, 2021

Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. June 14, 2021

Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. June 14, 2021

Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data. June 11, 2021

The Impact of Body Mass Index on Freedom From Therapeutic Intervention and Quality of Life in Active Surveillance Prostate Cancer Patients. June 11, 2021

5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer. June 11, 2021

PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study. June 11, 2021

Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. June 11, 2021

Prostate-specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer. June 10, 2021

Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study. June 10, 2021

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. June 10, 2021

Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort. June 10, 2021

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. June 10, 2021

Real world treatment utilization patterns in patients with castration-resistant prostate cancer. June 9, 2021

Page 10 of 1165